|[March 12, 2014]
Research and Markets: PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/clcw7s/pharmapoint)
has announced the addition of the "PharmaPoint:
Meningococcal Vaccines - Global Drug Forecast and Market Analysis to
2022: Event-Driven Update" report to their offering.
New Serogroup B Vaccines to Claim Half of Meningococcal Vaccines
Market by 2022
Upcoming and long-awaited market entries for Novartis' Bexsero and
Pfizer's MnB rLP2086 will prompt significant growth in the meningococcal
vaccines market over the next decade, states research and consulting
firm The authors.
According to the report, the arrival of these eagerly awaited serogroup
B vaccines will drive combined revenue for meningococcal vaccines across
the US, France, Germany, Italy, Spain, the UK, Japan, Australia, and
Brazil, from $1.2bn in 2012 to just over $2bn in 2022, increasing by 65%.
Novartis' Bexsero, which received approval from the European Medicines
Agency (EMA (News - Alert)) in January, is forecast to produce global sales of over
$330m by 2022, while Pfizer's MnB rLP2086, which is expected to launch
in the U in 2017 and in the EU the following year, is forecast to reach
total revenue of over $700m by 2022. Combined, these two products are
expected to dominate the meningococcal vaccines market by the end of the
forecast period, accounting for a 52% share.
According to Dr. Christopher Pace, The authors's analyst covering
infectious disease: Despite legitimate concerns from policymakers
regarding the cost-effectiveness of adding an additional vaccine to
already-crowded immunization schedules, serogroup B incorporation will
be well received by prescribers and patients, alike.
Novartis and Pfizer are expected to dominate this segment of the market,
with their respective products responsible for the majority of global
market growth over the next decade.
The authors's report states that the cost-effectiveness of meningococcal
vaccines is a universal barrier to global market growth, with the
inherently high cost per dose and relatively low incidence rates of
meningococcal disease leading to increased government skepticism in the
face of new vaccine launches and immunization program expansions.
Dr. Pace believes that while these concerns are not expected to
significantly prohibit the adoption of serogroup B vaccines, such as
Bexsero and MnB rLP2086, government assessment of cost-effectiveness is
considered to be a primary determinant of a vaccine's commercial success.
Key Topics Covered
Table of Contents
Opportunity and Unmet Need
Current and Future Players
For more information visit http://www.researchandmarkets.com/research/clcw7s/pharmapoint
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To TMCnet.com's Homepage ]